Zydus receives final nod from USFDA for Desmopressin Nasal Spray Solution

04 Oct 2017 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Desmopressin Nasal Spray Solution USP, 10 mcg/0.1 mL per Spray, 5 mL bottle. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Desmopressin Nasal Spray is indicated as an antidiuretic replacement therapy in the management of central diabetes insipidus, polyuria (excessive urination) and polydipsia (drinking excessive amounts of fluids) following head trauma or surgery in the pituitary region and nocturia (excessive urination at night).

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Zydus Lifesciences Share Price

919.90 -4.45 (-0.48%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×